Legend Biotech Corp
Business
Legend Biotech Corporation is a global biopharmaceutical company engaged in discovery, development, manufacturing and commercialization of novel cell therapies for oncology. The company's lead product, cilta-cel (CARVYKTI), is an autologous CAR-T cell therapy approved for relapsed or refractory multiple myeloma. Legend Biotech operates through subsidiaries in the United States, China and Europe, with a pipeline of autologous and allogeneic CAR-T and CAR-NK cell therapy candidates targeting various cancers. The company collaborates with Janssen Biotech on cilta-cel and has licensed DLL-3 CAR-T technology to Novartis.
Summary from 20-F filed 2026-03-10
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-296.80M |
| Total assets | $1.73B |
| Total liabilities | $731.60M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Legend Biotech Corp's CIK number?
Legend Biotech Corp's SEC CIK number is 0001801198 (1801198). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Legend Biotech Corp's SEC filings?
All of Legend Biotech Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.